Leading-edge radiation therapy offered by Loyola Medicine to broad range of cancer patients

NewsGuard 100/100 Score

Loyola Medicine is among the select centers that offer a broad range of cancer patients a leading-edge form of radiation therapy that is delivered during surgery.

The treatment is called intraoperative radiation therapy (IORT). After the tumor is removed, a concentrated dose of radiation is delivered to the tumor bed to kill any microscopic cancer cells left behind, thereby reducing the chance the cancer will recur.

Higher doses can be safely given because radiation is applied directly to the tumor site and doctors can move or shield healthy organs to protect them from the radiation, said Loyola Medicine radiation oncologist William Small, Jr., MD, chair of the department of radiation oncology, director of Loyola's Cardinal Bernardin Cancer Center and one of the nation's leading IORT experts.

Loyola is among the few centers that have the multidisciplinary expertise to use IORT on multiple cancers, including breast, gynecological, head and neck, pancreatic, colorectal, brain and bone cancers. In some patients, IORT is provided as a boost to standard radiation therapy that is given in sessions before or after surgery. In other cases, patients can receive all the radiation they need in one dose during surgery.

Breast cancer patient Marie Bartolo has a busy life, so she elected to have IORT during her lumpectomy rather than undergo traditional radiation treatments five days a week for four to six weeks.

The IORT was delivered by Dr. Small, working closely with breast surgeon Constantine Godellas, MD. "I got back my life really quickly," Ms. Bartolo said. "I think intraoperative radiation therapy helps you heal mentally and physically much more quickly."

Loyola physicians are helping to advance cancer care by conducting clinical trials on IORT and other treatments at the Cardinal Bernardin Cancer Center. The nationally renowned cancer center is recognized as high-performing by U.S. News & World Report and accredited by the American College of Surgeons Commission on Cancer.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer